The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
The ability to identify activated pathways that drive the growth and progression of cancer and to develop specific and potent inhibitors of key proteins in these pathways promises to dramatically change the treatment of cancer: A patient's cancer could be characterized at the molecular level and the information used to select the best treatment options. The development of successful therapies not only requires extensive target validation, but also new approaches to evaluating drug efficacy in animal models and in the clinic compared to the development of traditional cytotoxic agents. This article highlights Eli Lilly and Company's approach to developing targeted therapies, from target identification and validation through evaluation in the clinic. A selection of drugs in the Lilly Oncology pipeline is also discussed.
Perry
William L
WL
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. bperry@lilly.com
Weitzman
Aaron
A
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D004341:Drug Evaluation; D004345:Drug Industry; D004354:Drug Screening Assays, Antitumor; D005544:Forecasting; D006801:Humans; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins